1Jemal A,Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J C1in,2011,61(2) :69.
2Kotsafti A,Farinati F,Cardin R, et al. Autophagy and apoptosis- related genes in chronic liver disease and hepatocellular carcinoma [J]. BMC Gastroenterol, 2012,12 : 118.
4Chen N, Karantza-Wadsworth V. Role and regulation of autoph- agy in cancer[J]. Biochim Biophys Acta, 2009,1793(9) : 1516.
5Bao L,Chandra PK,Moroz K,et al. Impaired autophagy response in human hepatocellular carcinoma[J]. Experimental and Molecu- lar Pathology, 2014,96(2) : 149.
6Classon M, Harlow E. The retinoblastoma turnout suppressor in development and cancer[J]. Nat Rev Cancer, 2002,2(12) : 910.
7Anwar SL, Krech T, Hasemeier B, et al. Deregulation of RB1 ex- pressionby loss of imprinting in human hepatocellular carcinoma [J]. J Pathol,2014,233(4) ,392.
9Karakatsanis A,Papaconstantinou I,Gazouli M,et al. Expression of mieroRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c,miR-221 ,miR-222,and miR-223 in patients with hepa- tocellular carcinoma or intrahepatic eholangioearcinoma and its prognostic significance [J]. Molecular Carcinogenesis, 2013, 52 (4):297.
10Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment[J]. Cell, 2010, 141 (1):52.
二级参考文献58
1Research Center of Clinical Medicine,Affiliated Hospital of Nantong University,Nantong 226001,China (Yao M,Yao DF,Qiu LW,Wu W,Sai WL,Yang JL and Zhang HJ),Department of Oncology,Yancheng First People’s Hospital,Yancheng 224001,China (Bian YZ),Department of Oncology,Second Affiliated Hospital,Nanjing Medical University,Nanjing 210011,China (Zhang CG).Oncofetal antigen glypican-3 as a promising early diagnostic marker for hepatocellular carcinoma[J].Hepatobiliary & Pancreatic Diseases International,2011,10(3):289-294. 被引量：52
4Jemal A, Bray F, Center M M, et al. Global cancer statistics. CA Cancer J Clin, 2011, 61: 69-90.
5Liang X, Bi S, Yang W, et al. Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination. Vaccine, 2009, 27:6550-6557.
6Portolani N, Coniglio A, Ghidoni S, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg, 2006, 243:229-235.
7Shimada K, Sakamoto Y, Esaki M, et al. Analysis of prognostic factors affecting survival after initial recurrence and treatment efficacy for recurrence in patients undergoing potentially curative hepatectomy for hepatocellular carcinoma. Ann Surg Oncol, 2007, 14 2337-2347.
8Mao Y, Yang H, Xu H, et al. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut, 2010, 59: 1687-1693.
9States D J, Omenn G S, Blackwell T W, et al. Challenges in deriving high-confidence protein identifications from data gathered by a HUPO plasma proteome collaborative study. Nat Biotechnol, 2006, 24:333-338.
10Meng R, Gormley M, Bhat V B, et al. Low abundance protein enrichment for discovery of candidate plasma protein biomarkers for early detection of breast cancer. J Proteomics, 2011, 75:366-374.
6CARLOS R L, SILVIA T, ALEJANDRO F, et al. Manage- ment ofHCC [J]. J Hepatology, 2012, 56(Supl): S75-S87.
7GIANNINI E G, SAMMITO G, FARINATI F, et al. Determi- nants of alpha-fetoprotein levels in patients with hepatocel- lular carcinoma: implications for its clinical use [J]. Cancer, 2014, 120(6): 2150-2157.
8NOVAK J, FABIAN E Comments on the TNM classification of malignant tumours- 7th edition [J]. Klin Onkol, 2011, 24(2): 149-150.
9Bruix J, Sherman M ; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma : an update [ J ] . Hepatology, 2011, 53 (3): 1020-1022.
10Ba MC, Long H, Tang YQ, et al. GP73 expression and its significance in the diagnosis of hepatocellular carcinoma : a review[ J ]. Int J Clin Exp Pathol, 2012, 5 ( 9 ) : 874-881.
